OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C’s Potential as an Effective Treatment for Hair Loss

SUWON, South Korea

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the publication of preclinical research on the androgenetic alopecia (hair loss) treatment program, OLX104C, in Molecular Pharmaceutics.

The Company is developing the treatment for androgenetic alopecia based on cell-penetrating asymmetric siRNA (cp-asiRNA) platform technology. OLX104C reduces the expression of androgen receptor (AR), one of the key factors that cause androgenetic alopecia, which results in the suppression of the hair cycle transition from anagen to telogen phase.

The paper “Efficacy of Asymmetric siRNA Targeting Androgen Receptor for the Treatment of Androgenetic Alopecia” is based on the preclinical study on OLX104C, jointly conducted by OliX and the research team of Ik Jun Moon, M.D., Ph.D. & Chong-hyun Won, M.D., Ph.D. of University of Ulsan College of Medicine, Asan Medical Center. The research team demonstrated the efficacy of AR reduction, hair loss inhibition, and long duration of action in primary cultured human follicle dermal papilla cells (HFDPC) and rodent models of hair loss.

Dong Ki Lee, Ph.D., Founder and Chief Executive Officer of OliX said, “We are glad that, through this publication of our study in Molecular Pharmaceutics, the excellent efficacy of our cp-asiRNA targeting AR on hair loss has been verified by peer reviewers. We plan to submit a Human Research Ethics Application (HREA) for Phase 1 clinical trial near the end of this year, and we expect successful clinical results.”

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology.

Learn more: https://www.olixpharma.com/eng

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005053/en/